![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, June 10, 2023 10:49:04 AM
I hope that trial data from both the PREACH-M and the ACTIV-5 trials will be used to supplement the safety and efficacy levels for lenz that the FDA wants to see, to award our EUA for covid, in addition to obtaining approval from Australia to treat CMML, and maybe even get a Priority Review Voucher.
If a partnership is a fallback position for management, I'd hate to see them forced into it. But the keystone is the regulatory approval/authorization we need to commercialize lenz.
I'm excited about management's execution of their Nasdaq compliance plan.
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM